P2‐093: The Role of Neuropsychological Assessment in Predicting CSF Dementia Measures in Mild Cognitive Impairment

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

“…We selected participants with MCI who consecutively attended a memory clinic from a range of cohorts in various European countries: the Development of Screening Guidelines and Clinical Criteria for Predementia AD (DESCRIPA) multicenter study [12] (inclusion between 2003 and 2005, with an additional sample of participants seen outside the DE-SCRIPA inclusion period at one of the sites VU medical center (VUmc), inclusion between 1998 and 2007 [13]), LEARN multicenter study [14] (inclusion between 2009 and 2011), Ljubljana University Medical Centre [15] (inclusion between 2011 and 2014), and Karolinska University Hospital Huddinge memory clinic [16] (inclusion between 2007 and 2011).…”

“…Eligibility criteria for each cohort separately are described elsewhere [4,12,14,15,17]. Inclusion criteria for the present study were new referral to a memory clinic because of cognitive complaint; age 50 years or older; baseline diagnosis of MCI; baseline data of CSF markers of amyloid b 1-42 (Ab 1-42 ), total tau (t-tau), and phosphorylated tau (p-tau) levels; at least one follow-up measurement with information on progression to dementia; and no diagnosis of a somatic psychiatric or neurological disorder that might have caused the cognitive impairment at baseline.…”